All > Indiana > Milwaukee

SRK-181 for Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
CancerSRK-181 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, SRK-181, to see if it is safe and effective in treating solid tumors. The study will test different doses of the drug alone and in combination with another anti-cancer drug. The trial is divided into 3 parts, with a long-term extension phase.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
JTX-8064
1
a PD-1 inhibitor
1
agenT-797

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: 6 months

6 months
Anti-tumor activity of SRK-181, alone or in combination wit anti-PD-(L)1 antibody therapy as potential indicators of clinical response
Day 21
PK of SRK-181 alone and in combination with anti-PD-(L)1 antibody therapy
Day 21
Safety and tolerability of SRK-181 in combination with anti-PD-(L)1 antibody therapy
Safety and tolerability of single agent SRK-181

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
JTX-8064
1
a PD-1 inhibitor
1
agenT-797

Side Effects for

Arm B (Temsirolimus)
75%Fatigue
65%Anemia
48%Hyperglycemia
43%Lymphocyte count decreased
38%Anorexia
35%Constipation
35%Cough
35%Platelet count decreased
35%Nausea
30%Pain
30%Mucositis oral
28%White blood cell decreased
28%Hypoalbuminemia
28%Dyspnea
25%Hypertriglyceridemia
25%Alanine aminotransferase increased
25%Cholesterol high
23%Dysphagia
20%Depression
20%Fever
20%Weight loss
20%Hypophosphatemia
18%Hyponatremia
18%Insomnia
18%Alkaline phosphatase increased
18%Aspartate aminotransferase increased
18%Hypocalcemia
18%Hypokalemia
18%Headache
18%Non-cardiac chest pain
15%Peripheral sensory neuropathy
15%Creatinine increased
15%Vomiting
15%Edema face
15%Neck pain
13%Rash maculo-papular
13%Diarrhea
13%Dysgeusia
13%Rash acneiform
13%Infections and infestations - Other
10%Dizziness
10%Edema limbs
10%Arthralgia
10%Neutrophil count decreased
8%INR increased
8%Respiratory failure
8%Facial pain
8%Anxiety
8%Back pain
8%Pneumonitis
8%Hypertension
8%Dry mouth
8%Dry skin
8%Pruritus
8%Neck edema
8%Oral dysesthesia
5%Generalized muscle weakness
5%Sore throat
5%Hypomagnesemia
5%Tumor pain
5%General disorders and administration site conditions - Other
5%Urinary frequency
5%Myalgia
5%Hypernatremia
5%Chills
5%Dehydration
5%Ear pain
5%Epistaxis
5%Hypercalcemia
5%Hearing impaired
5%Pleural effusion
5%Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other
5%Allergic rhinitis
5%Skin infection
5%Gastroesophageal reflux disease
5%Dyspepsia
5%Leukocytosis
5%Papulopustular rash
5%Hyperkalemia
5%Lung infection
5%Lymphedema
5%Sinusitis
3%Anorectal infection
3%Peripheral motor neuropathy
3%Blurred vision
3%Oral pain
3%Respiratory, thoracic and mediastinal disorders - Other
3%Skin and subcutaneous tissue disorders - Other
3%Laryngeal obstruction
3%Vertigo
3%Pleuritic pain
3%Palmar-plantar erythrodysesthesia syndrome
3%Stridor
3%Tracheostomy site bleeding
3%Alopecia
3%Postnasal drip
3%Eye disorders - Other
3%Hypoxia
3%Heart failure
3%Pharyngeal hemorrhage
3%Tracheal hemorrhage
3%Pleural infection
3%Pneumothorax
3%Skin ulceration
3%Hypotension
This histogram enumerates side effects from a completed 2013 Phase 2 trial (NCT01256385) in the Arm B (Temsirolimus) ARM group. Side effects include: Fatigue with 75%, Anemia with 65%, Hyperglycemia with 48%, Lymphocyte count decreased with 43%, Anorexia with 38%.

Trial Design

4 Treatment Groups

Part A1: Dose Escalation
1 of 4
Long Term Extension Phase (LTEP)
1 of 4
Part B: Dose Expansion
1 of 4
Part A2: Dose Escalation
1 of 4

Experimental Treatment

200 Total Participants · 4 Treatment Groups

Primary Treatment: SRK-181 · No Placebo Group · Phase 1

Part A1: Dose Escalation
Biological
Experimental Group · 1 Intervention: SRK-181 · Intervention Types: Biological
Long Term Extension Phase (LTEP)Experimental Group · 2 Interventions: anti-PD-(L)1 antibody therapy, SRK-181 · Intervention Types: Biological, Biological
Part B: Dose ExpansionExperimental Group · 2 Interventions: anti-PD-(L)1 antibody therapy, SRK-181 · Intervention Types: Biological, Biological
Part A2: Dose EscalationExperimental Group · 2 Interventions: anti-PD-(L)1 antibody therapy, SRK-181 · Intervention Types: Biological, Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

Scholar Rock, Inc.Lead Sponsor
3 Previous Clinical Trials
522 Total Patients Enrolled
Lu Gan, MDStudy DirectorScholar Rock, Inc.

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a histologically documented solid tumor that is metastatic or locally advanced, for which there is no available therapy.
You have a history of anti-PD-(L)1 antibody nonresponse presenting (based upon the Investigator's assessment) either as progressive disease or stable disease (e.g., not improving, but also not worsening, clinically or radiographically) after at least 3 cycles of treatment with the most recent anti-PD-(L)1 antibody therapy (alone or in combination with chemotherapy) approved for that tumor type.
You have a history of primary nonresponse to anti-PD-1 therapy (alone or in combination with other therapy), presenting the best response (based upon the Investigator's assessment) either as progressive disease or stable disease (e.g.
Up to 3 lines of treatment are allowed between the last dose of anti-PD-1 and enrollment.
You have measurable disease per RECIST v1.1 as assessed at Screening.
Patient must have an Eastern Cooperative Oncology Group performance status (PS) 0-1.
Patients must have a genomic tumor aberrations for which a targeted therapy is available.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top